Unknown PHASE2 INTERVENTIONAL 4-arm NCT03806478

Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease

Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator For Mild to Moderate Cognitive Impairment Due to Alzheimer's Disease(AD)

Sponsor: Aphios

Conditions Alzheimer Disease 1 Alzheimer Disease 2 Alzheimer Disease 3 Dementia

Interventions APH-1105 Placebo

Updated 6 times since 2019 Last updated: Jul 26, 2021 Started: Jun 30, 2023 Primary completion: Sep 30, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Alzheimer Disease 1 and Alzheimer Disease 2 and is currently ongoing. Aphios leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Jan 2025 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Sep 2021 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2
Jan 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

Feb 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aphios

Data source: Aphios

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.